Uncategorized

Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2023 financial results.

cTRL Therapeutics today announced the appointment of Derrell D. Porter, M.D., as Chief Executive Officer.

Tract Bio today announced the publication of a research article in the American Journal of Respiratory and Critical Care Medicine (AJRCCM) highlighting the stem cell variants driving chronic lung inflammation in modulator-treated cystic fibrosis patients (CFTR modulators).

Kazia Therapeutics Limited is pleased to provide a preliminary update from the ongoing investigator-initiated Phase 2 clinical trial (NCT04906096) evaluating paxalisib as monotherapy treatment in patients with relapsed/refractory primary central nervous system lymphoma (r/r PCNSL).

Seagen Inc. (Nasdaq:SGEN) (Seagen or the Company) reported financial results today for the third quarter ended September 30, 2023.

PolyBio Research Foundation has announced a $15M gift from Kanro: a philanthropic fund to support scientific research established by Vitalik Buterin , co-founder of Ethereum.

IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, announced third quarter results.

West Pharmaceutical Services, Inc. announced that it will present at Jefferies Healthcare Conference in London, UK on Tuesday, November 14, 2023 at 10:00 AM GBT.

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that company management will participate in the following conferences and invited investors to participate by webcast.

Merck, known as MSD outside of the United States and Canada, announced that the Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, met its key secondary endpoint of overall survival, for the adjuvant treatment of patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection